Dr Johanna Chiffelle and Prof. Alexandre Harari (UNIL) have received Innosuisse funding for the IMPRINT project, which combines a patented high-resolution immune-repertoire sequencing technology with AI-based analytics to predict, before treatment begins, which cancer patients will respond to immunotherapy.
L’IA à l’Université de Lausanne